Point Biopharma stock nearly doubles on Eli Lilly deal

October 04, 2023 01:29 AM AEDT | By Invezz

Point Biopharma stock nearly doubles on Eli Lilly deal — Image source: Invezz

Details of Lilly-Point agreement

Lilly is willing to pay about $1.4 billion for Point Biopharma that values each of its share at $12.50 or at an 87% premium versus their previous close.

The Nasdaq-listed firm is expected to announce results of a Phase III trial of PNT2002 (prostate cancer treatment) before the end of this year. Joe McCann – its Chief Executive said in a press re l ease today:

The combination could significantly accelerate the discovery, development and global access to radiopharmaceuticals.

The news arrives only a few months after Eli Lilly & Co said it was spending $1.925 billion on buying Versanis Bio to expand its footprint in obesity drugs.

Deal to close by the end of 2023

Lilly expects this transaction to complete before the start of 2024 provided that it satisfies the customary closing conditions including shareholders’ approval.

Reacting to the agreement announced today, Faisal Khurshid – a Leerink Partners analyst said the pharmaceutical behemoth has valued Point Biopharma stock at our “best-case scenario” after the PNT2002 data.

Goldman Sachs and Centerview Partners are serving as exclusive financial advisors of Eli Lilly & Co and Point Biopharma Global Inc on the all deal, respectively. Boards of both companies have already approved the all-cash transaction.

Lilly is expected to report its Q3 financial results in early November. Consensus is for it to earn $2.88 per share versus $1.98 a share last year. Shares of the New York listed firm are in the red at writing.

The post Point Biopharma stock nearly doubles on Eli Lilly deal appeared first on Invezz.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.